Benefits
Supports Mood and Emotional Well-Being
Multiple randomized trials of saffron extract (30 mg/day) standardized to crocin show improvements in mood and depressive symptom scores in adults with mild-to-moderate depression, with effects comparable to certain pharmaceutical comparators in head-to-head trials.
Supports Macular and Retinal Function
Crocin and crocetin have been studied in early age-related macular degeneration, with saffron supplementation (20 mg/day) showing improvements in retinal flicker sensitivity and macular focal-ERG parameters over short-term use.
Improves Sleep Quality
Isolated crocetin (7.5 mg/day) increased EEG delta-wave activity and improved subjective sleepiness on rising and feeling refreshed in adults with mild sleep complaints in a randomized crossover study.
Modest Effects on Some Cardiovascular Risk Factors
A meta-analysis of saffron and crocin trials found no significant change in blood lipids (total cholesterol, LDL-C, or triglycerides). It did report small reductions in diastolic blood pressure, body weight, and waist circumference, plus lower fasting glucose in the higher-quality studies.
Potent Carotenoid Antioxidants
Crocin and crocetin scavenge reactive oxygen species, modulate Nrf2, and protect neuronal and retinal cells from oxidative damage in laboratory and animal studies.
Mechanism of action
Serotonergic and Dopaminergic Modulation
Crocin and crocetin appear to inhibit synaptic reuptake of serotonin, dopamine, and norepinephrine in preclinical models, providing a plausible mechanism for the antidepressant signal observed in human trials.
Retinal Cell Protection
Crocetin protects retinal pigment epithelium and photoreceptors from light-induced and oxidative damage in cell and animal models, supporting the macular function findings.
Sleep Architecture Modulation
Crocetin enhances EEG delta-wave (slow-wave) activity and supports sleep continuity, possibly via GABAergic modulation and antioxidant action on stress pathways.
Lipid Metabolism Modulation
Crocin influences hepatic lipid handling, reduces LDL oxidation, and supports HDL-related transport in animal models, contributing to the cardiovascular risk-factor signal in clinical trials.
Nrf2 / Antioxidant Pathway Activation
Both crocin and crocetin upregulate the Nrf2 transcription factor and downstream antioxidant enzymes (HO-1, NQO1), supporting cellular resilience against oxidative stress.
Clinical trials
6-week, randomized, double-blind, placebo-controlled trial of saffron capsules (30 mg/day) in adults with mild-to-moderate depression. Outcome: Hamilton Depression Rating Scale (HAM-D).
40 adult outpatients with mild-to-moderate depression.
Saffron significantly reduced HAM-D scores vs placebo at 6 weeks, with minimal adverse events. Established saffron's antidepressant signal and led to subsequent comparator trials vs fluoxetine and imipramine showing comparable efficacy at the doses used.
3-month, randomized, double-blind, placebo-controlled crossover trial of saffron (20 mg/day) vs placebo in patients with early AMD. Outcome: focal electroretinogram (fERG) flicker sensitivity, visual acuity.
25 patients with early AMD; 3-month intervention.
Over 3 months, saffron improved focal-ERG flicker amplitude and lowered flicker thresholds versus placebo in this small crossover trial (25 patients). This is a short-term retinal-function (surrogate) result in an early-AMD population, not a measure of preserved vision or slowed disease progression.
Randomized, double-blind, placebo-controlled crossover study of crocetin (7.5 mg/day) for 14 days vs placebo in adults with mild sleep complaints. Outcomes: single-channel EEG (delta power), subjective sleep ratings.
30 adults with mild sleep complaints.
Crocetin significantly increased EEG delta-power activity and improved subjective sleepiness on rising and feeling refreshed vs placebo. No significant differences in sleep latency, efficiency, or total sleep time, suggesting crocetin supports sleep quality more than initiation.